Eli Lilly Shares Rise 4% as Q3 Earnings Exceed Estimates and Revenue Outlook Increases
Eli Lilly (LLY) reported Q3 2026 earnings of $7.48 per share, beating estimates of $5.60, with revenue up 39% YoY to $24.4B. Mounjaro and Zepbound drove growth, with revenues of $10.7B and $5.4B, respectively. The company raised its full-year revenue guidance to $91B–$92B but lowered EPS guidance due to R&D charges. Shares rose 4% in premarket trading.
How this was made
The 30-second read
Why it matters
The earnings beat and raised revenue outlook are likely to attract short‑term buying, while the EPS guidance reduction may temper longer‑term enthusiasm.
Market read
The report is a primary earnings disclosure with material numbers, driving immediate price movement and sector‑wide implications.
What to watch
Acquired in‑process R&D charges of $4.57 per share may recur, and the guidance assumes sustained demand for new oncology products.
Background
Eli Lilly's Q3 results showcase record sales from its diabetes and weight‑loss portfolio, with a notable revenue surge and a modest EPS outlook adjustment.
Ticker impact
Eli Lilly reported Q3 2026 earnings beating EPS estimates and raised full-year revenue guidance, causing a >4% pre‑market share rise.
upward pressure as the market prices in the revenue beat and raised guidance, offset partially by the EPS guidance reduction
Strong sales of Mounjaro and Zepbound lifted revenue 39% YoY; guidance now $91‑$92B versus $88.7B consensus, a material upside that typically fuels price gains.
Market effects
Boosts the broader pharma/biotech sector, especially peers with obesity‑treatment pipelines.
Positive for U.S. large‑cap healthcare stocks in the NYSE composite.
Highlights continued demand for obesity drugs worldwide, may influence global health‑care indices.
Counterpoint
The EPS guidance cut could signal margin pressure from R&D spend, suggesting caution on the upside.
Key entities
- ExecutiveDavid A. Ricks
Chairman and CEO of Eli Lilly, provided commentary on the results.
